Impact of early cessation of dual antiplatlet therapy on intrastent condition of Resolute zotalolimus-eluting stent 9 months after stent implantation.

Impact of early cessation of dual antiplatlet therapy on intrastent condition of Resolute zotalolimus-eluting stent 9 months after stent implantation. - Impact of early cessation of dual antiplatlet therapy on intrastent condition of Resolute zotalolimus-eluting stent 9 months after stent implantation.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011300

Enrollment

Registered

2013-08-01

Start date

2013-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patient with coronary artery disease implanted Resolute zotarolimus-eluting stent.

Interventions

3 months cessastion of dual antiplatelet therapy cotinue of dual antiplatelet therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient implanted Resolute zotarolimus-eluting stent by optical coherence tomograpy guidance.

Exclusion criteria

Exclusion criteria: acute myocardial infarction chronic renal failure (Cr>2.0mg/dL) lefe main trunk disease severe calcified disease

Design outcomes

Primary

Measure	Time frame
Intrastent thrombus and neointimal coverage of Resolute zotarolimus-eluting 9 months after stent implantation.	—

Countries

Japan

Contacts

Public ContactTakahiro Sawada

Hyogo Brain and Heart Center Division of Cardiovascular Medicine

taktak319@yahoo.co.jp079-293-3131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026